Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 30 days matching "hemophilia management"

Drug approvalRSS4 days ago

Data show hemophilia bleeds can be successfully treated while on Hympavzi

Hympavzi is a new injection medicine approved in 2024 to help prevent bleeding in people with hemophilia. In the large study that led to its approval, the medicine worked well at stopping bleeds before they happened. When breakthrough bleeds did occur, doctors were able to treat them successfully using standard blood clotting medicines.

WHY IT MATTERSIf you have hemophilia, this news shows that Hympavzi can reduce bleeding episodes while still allowing doctors to treat any bleeds that do happen with familiar, proven treatments—meaning you don't have to choose between prevention and effective emergency care.
💬 Ask your doctorHemophilia AHemophilia B
Clinical trialRSSMay 8

Denecimig excels at reducing bleeds in hemophilia A patients: Study

A new medicine called denecimig (Mim8) was tested in a study called FRONTIER2 and worked better than current treatments at stopping bleeding episodes in people with hemophilia A. The medicine was given either once a month or once a week, and it worked well for both adults and teenagers 12 years and older, even for patients whose bodies have developed resistance to other treatments.

WHY IT MATTERSIf denecimig gains approval, hemophilia A patients—especially those with inhibitors who have limited treatment options—could switch to a once-monthly injection that reduces bleeds more effectively than their current preventive regimens.
💬 Ask your doctorhemophilia Ahemophilia A with inhibitors
PipelineRSSMay 5

FDA grants fast track status to 1-time stem cell therapy for hemophilia A

The FDA has given special fast-track status to a new stem cell therapy being developed by Expression Therapeutics for hemophilia A, a bleeding disorder. This designation means the therapy can be reviewed faster than usual. The therapy is designed to be a one-time treatment that could provide lasting relief from hemophilia A symptoms.

WHY IT MATTERSIf successful, this one-time stem cell therapy could eliminate the need for regular blood clotting factor infusions that hemophilia A patients currently require multiple times per week.
💬 Ask your doctorhemophilia A
Clinical trialRSSApr 24

Single infusion of Roctavian linked to fewer bleeds in hemophilia A

A new treatment called Roctavian was given as a single injection to men with severe hemophilia A (a bleeding disorder). Seven years later, most patients had fewer bleeding episodes and needed less preventive medicine. This suggests the treatment's benefits can last for many years.

WHY IT MATTERSIf you have severe hemophilia A, Roctavian could mean switching from frequent infusions or injections to a single treatment that protects you from bleeds for years.
💬 Ask your doctorHemophilia A

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases